Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ; CLARITY Study Group. Cook S, et al. Among authors: sorensen ps. Mult Scler. 2011 May;17(5):578-93. doi: 10.1177/1352458510391344. Epub 2011 Jan 12. Mult Scler. 2011. PMID: 21228029 Clinical Trial.
Principles of a new treatment algorithm in multiple sclerosis.
Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Hartung HP, et al. Among authors: sorensen ps. Expert Rev Neurother. 2011 Mar;11(3):351-62. doi: 10.1586/ern.11.15. Expert Rev Neurother. 2011. PMID: 21375441 Review.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A; CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group. Ali S, et al. Among authors: sorensen ps. Clin Drug Investig. 2012 Jan 1;32(1):15-27. doi: 10.2165/11593310-000000000-00000. Clin Drug Investig. 2012. PMID: 22017519 Clinical Trial.
Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans.
Brambilla P, Esposito F, Lindstrom E, Sorosina M, Giacalone G, Clarelli F, Rodegher M, Colombo B, Moiola L, Ghezzi A, Capra R, Collimedaglia L, Coniglio G, Celius EG, Galimberti D, Sørensen PS, Martinelli V, Oturai AB, Harbo HF, Hillert J, Comi G, Martinelli-Boneschi F. Brambilla P, et al. Among authors: sorensen ps. Neurosci Lett. 2012 Nov 21;530(2):155-60. doi: 10.1016/j.neulet.2012.10.008. Epub 2012 Oct 13. Neurosci Lett. 2012. PMID: 23069673
394 results